License with Sana Biotechnology

Aug 09, 2021
RNS Number : 9261H
MaxCyte, Inc.
09 August 2021
 

 

 

 

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

 

Agreement represents MaxCyte's 14th strategic platform license (SPL)

 

 Sana will use MaxCyte's Flow Electroporation® technology and ExPERTplatform in conjunction with the development of its hypoimmune cell therapy programs

 

GAITHERSBURG, MD, 9 August 2021 - MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.

 

Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related milestone payments.

Doug Doerfler, President and CEO of MaxCyte, said: "We are delighted to support Sana's ex vivo cell therapy programs and recognize the potential of the company's novel hypoimmune cell platform to advance treatments for serious diseases. This agreement represents an important achievement for MaxCyte as we continue to expand the use of our next-generation technology platform to support the development of innovative treatments."

MaxCyte's ExPERT instrument portfolio represents the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

 

About MaxCyte

 

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

 

MaxCyte Contacts:

MaxCyte Inc.

 

Doug Doerfler, Chief Executive Officer

 

Amanda Murphy, Chief Financial Officer

 

 

 

 

+1 301-944-1660

 

 

 

Nominated Adviser and Joint Corporate Broker

 

Panmure Gordon

 

Emma Earl / Freddy Crossley

 

Corporate Broking

 

Rupert Dearden

 

 

 

 

+44 (0)20 7886 2500

   

Joint Corporate Broker

 

Numis Securities Limited

 

James Black / Duncan Monteith / Matthew  O'Dowd

 

 

 

 

+44 (0)20 7260 1000

   

Joint Corporate Broker

 

Stifel Nicolaus Europe Limited

 

Healthcare Investment Banking

 

Nicholas Moore / Ben Maddison / Samira Essebiyea

 

Corporate Broking

 

Nick Adams

 

 

 

 

+44 (0)20 7710 7600

 

   

UK IR Adviser

 

Consilium Strategic Communications

 

Mary-Jane Elliott

 

Chris Welsh

 

 

 

 

+44 (0)203 709 5700

 

maxcyte@consilium-comms.com

 

   

US IR Adviser

 

Gilmartin Group

 

David Deuchler, CFA

 

 

 

 

+1 415-937-5400

 ir@maxcyte.com

 

   

US Media Relations

 

Jamie Lacey-Moreira

 

PressComm PR, LLC

 

 

+1 410-299-3310

 

jamielacey@presscommpr.com

   

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQVLFBFVLZBBK